Search results for "Estro."

showing 10 items of 770 documents

Decreased bioavailability of nitric oxide in aorta from ovariectomized senescent mice. Role of cyclooxygenase.

2015

This study investigates the effects of aging and/or ovariectomy on vascular reactivity to thromboxane A2 (TXA2) receptor stimulation with U46619, and the modulation by nitric oxide (NO) and cyclooxygenase (COX) in aorta from female senescence-accelerated mice (SAMP8) and from senescence resistant mice (SAMR1). Five-month-old female SAMR1 and SAMP8 were divided into three groups: sham-operated, ovariectomized and ovariectomized plus estradiol. Twenty-eight days after surgery, thoracic aortic rings were mounted for isometric recording of tension and concentration-response curves for U46619 (10(-10)-3 × 10(-7) M) were performed in the absence and in the presence of the NO synthase inhibitor N(…

0301 basic medicineAgingReceptors ThromboxaneAorta Thoracic030204 cardiovascular system & hematologyBiochemistrychemistry.chemical_compoundThromboxane A2Mice0302 clinical medicineEndocrinologySuperoxidesThoracic aortaVasoconstrictor AgentsbiologyEstradiolSuperoxideEstrogen Replacement TherapyAge FactorsOvariectomized ratFemaleMenopauseSignal Transductionmedicine.medical_specialtymedicine.drug_classOvariectomyDown-RegulationNitric OxideNitric oxide03 medical and health sciencesThromboxane A2medicine.arteryInternal medicineGeneticsmedicineAnimalsCyclooxygenase InhibitorsMolecular BiologyAortaDose-Response Relationship Drugbusiness.industryCell BiologyEnzyme ActivationOxidative Stress030104 developmental biologyEndocrinologychemistryEstrogenProstaglandin-Endoperoxide SynthasesVasoconstrictionbiology.proteinCyclooxygenaseNitric Oxide SynthasebusinessExperimental gerontology
researchProduct

Estrogenic regulation of skeletal muscle proteome : a study of premenopausal women and postmenopausal MZ cotwins discordant for hormonal therapy

2017

Female middle age is characterized by a decline in skeletal muscle mass and performance, predisposing women to sarcopenia, functional limitations, and metabolic dysfunction as they age. Menopausal loss of ovarian function leading to low circulating level of 17b-estradiol has been suggested as a contributing factor to aging-related muscle deterioration. However, the underlying molecular mechanisms remain largely unknown and thus far androgens have been considered as a major anabolic hormone for skeletal muscle. We utilized muscle samples from 24 pre- and postmenopausal women to establish proteome-wide profiles, associated with the difference in age (30–34 years old vs. 54– 62 years old), men…

0301 basic medicineAgingnaisetlabel‐free protein quantitationProteomeAnabolismvaihdevuodetmedicine.medical_treatmentTwinsmenopausenano‐LC‐HD‐MSElihakset0302 clinical medicineSTRENGTHBRAIN315 Sport and fitness sciencesta315luustoINHIBITORHormone replacement therapy (menopause)ta3142MITOCHONDRIAL BIOGENESISMiddle AgedPostmenopauseMenopauseREPLACEMENThormone replacement therapyEditorialmedicine.anatomical_structurehormonihoitoHormonal therapyOriginal ArticleFemalemuscleswomenAdultestrogeenitnano-LC-HD-MSEEXPRESSIONmedicine.medical_specialtyBiologyestrogenic regulation03 medical and health sciencesmitochondrial functionInternal medicinemedicineHumansMuscle Skeletallabel-free protein quantitationmuscle proteomeAgedSkeletal muscleEstrogenslabel-free proteinquantitationOriginal ArticlesCell Biologyfunctional annotationmedicine.diseaseMiddle ageMONOZYGOTIC TWIN PAIRS030104 developmental biologyEndocrinologyPremenopauselihasmassaSarcopeniaCELLS3111 BiomedicineEnergy Metabolismfemale muscle030217 neurology & neurosurgeryskeletal musclesHormone
researchProduct

A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Can…

2017

AbstractSomatic mutations of the Estrogen Receptor α (ERα) occur with an up to 40% incidence in ER sensitive breast cancer (BC) patients undergoing prolonged endocrine treatments. These polymorphisms are implicated in acquired resistance, disease relapse, and increased mortality rates, hence representing a current major clinical challenge. Here, multi-microseconds (12.5 µs) molecular dynamics simulations revealed that recurrent ERα polymorphisms (i. e. L536Q, Y537S, Y537N, D538G) (mERα) are constitutively active in their apo form and that they prompt the selection of an agonist (active)-like conformation even upon antagonists binding. Interestingly, our simulations rationalize, for the firs…

0301 basic medicineAgonistModels MolecularBreast cancerComputational chemistryMolecular dynamicsSomatic cellmedicine.drug_classlcsh:MedicineEstrogen receptorBreast Neoplasms-Molecular Dynamics SimulationPolymorphism Single NucleotideArticleProtein Structure SecondaryEstrogen Receptor Antagonists03 medical and health sciences0302 clinical medicineBreast cancermedicineEndocrine systemHumanslcsh:ScienceMultidisciplinarybusiness.industrylcsh:REstrogen Receptor alphamedicine.diseaseEstrogen Receptor Antagonist030104 developmental biologySelective estrogen receptor modulator030220 oncology & carcinogenesisCancer researchlcsh:QFemaleEstrogen Receptor AntagonistsbusinessEstrogen receptor alphaBreast NeoplasmHuman
researchProduct

Estradiol, acting through ERα, induces endothelial non-classic renin-angiotensin system increasing angiotensin 1–7 production

2016

Intracellular renin-angiotensin system (RAS) can operate independently of the circulating RAS. Estrogens provide protective effects by modulating the RAS. Our aim was to investigate the effect of estradiol (E2) on angiotensin converting enzymes (ACE) 1 and ACE2 expression and activities in human endothelial cells (HUVEC), and the role of estrogen receptors (ER). The results confirmed the presence of active intracellular RAS in HUVEC. Physiological concentrations of E2 induced a concentration-dependent increase of ACE1 and ACE2 mRNA expression and ACE1, but not ACE2, protein levels. ACE1 and ACE2 enzymatic activities were also induced with E2. These effects were mediated through ERα activati…

0301 basic medicineAgonistmedicine.medical_specialtymedicine.drug_classEstrogen receptorPeptidyl-Dipeptidase A030204 cardiovascular system & hematologyBiologyBiochemistryEstrogen Receptor AntagonistsCiencias Biológicas03 medical and health sciences0302 clinical medicineEndocrinologyPiperidinesInternal medicineRenin–angiotensin systemHuman Umbilical Vein Endothelial CellsmedicineHumansFulvestrantMolecular BiologyESTROGEN RECEPTORDose-Response Relationship DrugEstradiolEstrogen Receptor alphaANGIOTENSIN CONVERTING ENZYMESBioquímica y Biología MolecularRENIN ANGIOTENSIN SYSTEMPeptide FragmentsEndothelial stem cellESTROGEN030104 developmental biologyEndocrinologyGene Expression RegulationEstrogenENDOTHELIAL CELLPyrazolesAngiotensin-Converting Enzyme 2Estrogen Receptor AntagonistsAngiotensin IEstrogen receptor alphaCIENCIAS NATURALES Y EXACTAShormones hormone substitutes and hormone antagonistsIntracellularMolecular and Cellular Endocrinology
researchProduct

Cytotoxic effects of zearalenone and its metabolites and antioxidant cell defense in CHO-K1 cells.

2016

Zearalenone (ZEA) and its metabolites (α-zearalenol; α-ZOL, β-zearalenol; β-ZOL) are secondary metabolites of Fusarium fungi that produce cell injury. The present study explores mycotoxin-induced cell damage and cellular protection mechanisms in CHO-K1 cells. Cytotoxicity has been determined by reactive oxygen species (ROS) production and DNA damage. ROS production was determined using the fluorescein assay and DNA strand breakage by comet assay. Intracellular protection systems were glutathione (GSH), glutathione peroxidase (GPx), catalase (CAT) and superoxide dismutase (SOD). The results demonstrated that all mycotoxins increased the ROS levels up to 5.3-fold the control levels in CHO-K1 …

0301 basic medicineAntioxidantDNA damagemedicine.medical_treatmentImmunoblottingCHO CellsToxicologyAntioxidantsSuperoxide dismutase03 medical and health scienceschemistry.chemical_compoundCricetulusCricetinaemedicineAnimalsEstrogens Non-SteroidalCell damagechemistry.chemical_classificationReactive oxygen speciesGlutathione PeroxidasebiologySuperoxide DismutaseGlutathione peroxidasefood and beveragesGeneral MedicineGlutathionemedicine.diseaseCatalaseGlutathioneComet assay030104 developmental biologychemistryBiochemistrybiology.proteinZearalenoneZeranolComet AssayReactive Oxygen SpeciesOxidation-ReductionFood ScienceDNA DamageFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct

Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer’s Disease

2016

Amyloid-b (Ab) clearance from brain, which is decreased in Alzheimer's disease, is facilitated by apolipoprotein E (ApoE). ApoE is upregulated by activation of the retinoid X receptor moiety of the RXR/PPAR dimeric receptor. As we have previously demonstrated, estrogenic compounds, such as genistein, have antioxidant activity, which can be evidenced by increased expression of manganese superoxide dismutase (MnSOD). Furthermore, genistein is a non-toxic, well-tested, and inexpensive drug that activates PPARg receptor. We isolated and cultured cortical astrocytes from dissected cerebral cortices of neonatal mice (C57BL/6 J). Preincubation with genistein (5 mM) for 24 hours, prior to the addit…

0301 basic medicineApolipoprotein EApolipoprotein BPeroxisome proliferator-activated receptorGenisteinPlaque Amyloid01 natural sciencesBiochemistrychemistry.chemical_compound0302 clinical medicine030212 general & internal medicineReceptorCells CulturedNootropic Agentschemistry.chemical_classificationbiologyGeneral NeuroscienceBrainGeneral MedicineGenisteinPsychiatry and Mental healthClinical PsychologyNeuroprotective AgentsFemalePeroxisome proliferator-activated receptor gammamedicine.medical_specialtyTetrahydronaphthalenesMice TransgenicRetinoid X receptor03 medical and health sciencesApolipoproteins EDownregulation and upregulationAlzheimer DiseaseIn vivoPhysiology (medical)Internal medicineAvoidance LearningmedicineAnimalsHabituation PsychophysiologicMaze LearningAmyloid beta-PeptidesRecognition PsychologyOlfactory Perception0104 chemical sciencesMice Inbred C57BLPPAR gamma010404 medicinal & biomolecular chemistryDisease Models Animal030104 developmental biologyEndocrinologychemistryBexaroteneAstrocytesbiology.proteinPhytoestrogensGeriatrics and Gerontology030217 neurology & neurosurgeryJournal of Alzheimer's Disease
researchProduct

Reaction of zearalenone and α-zearalenol with allyl isothiocyanate, characterization of reaction products, their bioaccessibility and bioavailability…

2017

This study investigates the reduction of zearalenone (ZEA) and α-zearalenol (α-ZOL) on a solution model using allyl isothiocyanate (AITC) and also determines the bioaccessibility and bioavailability of the reaction products isolated and identified by MS-LIT. Mycotoxin reductions were dose-dependent, and ZEA levels decreased more than α-ZOL, ranging from 0.2 to 96.9% and 0 to 89.5% respectively, with no difference (p⩽0.05) between pH 4 and 7. Overall, simulated gastric bioaccessibility was higher than duodenal bioaccessibility for both mycotoxins and mycotoxin-AITC conjugates, with duodenal fractions representing ⩾63.5% of the original concentration. Simulated bioavailability of reaction pro…

0301 basic medicineBiological AvailabilityAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyIsothiocyanatesChemical reductionOrganic chemistryHumansFood scienceEstrogens Non-SteroidalMycotoxinCytotoxicityZearalenonefood and beverages04 agricultural and veterinary sciencesGeneral MedicineMycotoxinsAllyl isothiocyanate040401 food scienceIn vitroBioavailability030104 developmental biologychemistryToxicityZearalenoneZeranolCaco-2 CellsFood ScienceFood chemistry
researchProduct

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

2018

AbstractPurpose: This study aimed to identify biomarkers of resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancers treated with prolonged neoadjuvant letrozole.Experimental Design: We performed targeted DNA and RNA sequencing in 68 ER+ breast cancers from patients treated with preoperative letrozole (median, 7 months).Results: Twenty-four tumors (35%) exhibited a PEPI score ≥4 and/or recurred after a median of 58 months and were considered endocrine resistant. Integration of the 47 most upregulated genes (log FC > 1, FDR < 0.03) in letrozole-resistant tumors with transcription-binding data showed significant overlap with 20 E2F4-regulated genes (P =…

0301 basic medicineCancer ResearchBreast NeoplasmsE2F4 Transcription FactorArticle03 medical and health sciences0302 clinical medicineText miningDownregulation and upregulationCell Line TumorBiomarkers TumormedicineHumansEndocrine systemProtein Kinase InhibitorsE2F4GeneAgedCell ProliferationAged 80 and overAromatase Inhibitorsbusiness.industryGene Expression ProfilingLetrozoleEndocrine therapyComputational BiologyMiddle AgedEMTREE drug terms: aromatase inhibitorcyclin dependent kinase 4cyclin dependent kinase 6cyclin dependent kinase inhibitorfulvestrantletrozolepaclitaxelpalbociclibtranscription factor E2F4estrogen receptorletrozoleprotein kinase inhibitortranscription factor E2F4transcriptometumor marker030104 developmental biologyReceptors EstrogenOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisLetrozoleMutationRetreatmentCancer researchFemaleTranscriptomebusinessmedicine.drug
researchProduct

The Secreted Protein C10orf118 Is a New Regulator of Hyaluronan Synthesis Involved in Tumour-Stroma Cross-Talk.

2021

Simple Summary Hyaluronan is a main glycosaminoglycan in extracellular matrix with an important role in breast cancer progression. Alterations in its synthesis and size may affect tu-mour growth and metastasis. Communication between stromal and breast cancer cells consists of the secretion of factors that provoke a series of cell signalling that influence cell fate and tis-sue microenvironment, by favouring tumour cell survival and motility. Here, we present the c10orf118 protein expressed in high amounts by breast tumour cells as a new regulator in hya-luronan synthesis. This protein is found both in Golgi and secreted in the extracellular matrix, whereas its role is still unknown. The sec…

0301 basic medicineCancer ResearchChemokineBreast cancer; Estrogen receptor; Golgin104; Hyaluronan; Hyaluronan synthase 2; MCF-7; MDA-MB-231; Tumour microenvironmentMDA-MB-231Estrogen receptorBiologyHyaluronan Synthase 2lcsh:RC254-282ArticlehyaluronanGlycosaminoglycan03 medical and health scienceshyaluronan synthase 2breast cancer0302 clinical medicinemedicineSecretionCancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseCell biology030104 developmental biologyOncologyMCF-7030220 oncology & carcinogenesisCancer cellbiology.proteingolgin104MCF-7tumour microenvironmentestrogen receptorCancers
researchProduct

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to succ…

2019

Purpose: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. Unlike the well-characterized and easily manageable safety profile of endocrine therapies, adverse events associated with targeted therapies are complex and potentially severe. Their prompt recognition and treatment, crucial for prolonged endocrine sensitivity and survival, may be challenging and requires a multidisciplinary effort and a good knowledge of drug interactions. Methods:…

0301 basic medicineCancer ResearchReviewDiseasechemistry.chemical_compound0302 clinical medicineRibociclibMolecular Targeted TherapyAbemaciclibClinical Trials as TopicDisease ManagementMetastatic breast cancerEverolimuOncologyReceptors Estrogen030220 oncology & carcinogenesisFemaleAdvanced breast cancerReceptors ProgesteroneBreast Neoplasmmedicine.drugHumanmedicine.medical_specialtyNeutropeniaDrug-Related Side Effects and Adverse ReactionsAntineoplastic Agents HormonalProtein Kinase InhibitorBreast NeoplasmsPalbociclibPalbociclib03 medical and health sciencesBreast cancermedicineBiomarkers TumorHumansEverolimusIntensive care medicineAdverse effectProtein Kinase InhibitorsEverolimusbusiness.industrymedicine.diseaseClinical trialAbemaciclib030104 developmental biologychemistryMED/06 - ONCOLOGIA MEDICAbusinessDrug-Related Side Effects and Adverse ReactionAbemaciclib; Advanced breast cancer; Everolimus; Neutropenia; Palbociclib; Ribociclib
researchProduct